Drug Combination Details
| General Information of the Combination (ID: C04478) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | hu14.18-IL2 immunicytokine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Adrenocortical carcinoma
[ICD-11: 2D11]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | GD2 | Molecule Info | ||
| In-vitro Model | NXS2 | Neuroblastoma | Rattus norvegicus | |||
| In-vivo Model | NXS2 tumors were induced in A/J mice by injecting 2*106 cells in 100 mcL PBS subcutaneously on the left flank proximal to the spleen. | |||||
| Experimental
Result(s) |
RV in combination with IC provided an enhanced anti-tumor treatment in preclinical model as it lowered the tumor burden and increased survival. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8. | |||
